(NASDAQ: NYXH) Nyxoah Sa's forecast annual revenue growth rate of 153.71% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 10.18%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Nyxoah Sa's revenue in 2025 is $4,903,370.On average, 3 Wall Street analysts forecast NYXH's revenue for 2025 to be $412,298,751, with the lowest NYXH revenue forecast at $351,442,018, and the highest NYXH revenue forecast at $510,133,622. On average, 3 Wall Street analysts forecast NYXH's revenue for 2026 to be $1,549,226,780, with the lowest NYXH revenue forecast at $1,258,678,922, and the highest NYXH revenue forecast at $1,926,007,057.
In 2027, NYXH is forecast to generate $3,183,563,161 in revenue, with the lowest revenue forecast at $3,183,563,161 and the highest revenue forecast at $3,183,563,161.